Introduction

Perinatal and pediatric diseases related to neurovascular disorders cause significant problems during life, affecting a population with a long life expectancy. Early diagnosis and assessment of the severity of these diseases are crucial to establish an appropriate neuroprotective treatment. Currently, physical examination, neuroimaging and clinical judgment are the main tools for diagnosis, although these tests have certain limitations. There is growing interest in the potential value of noninvasive biomarkers that can be used to monitor child patients at risk of brain damage, allowing accurate, and reproducible measurements.

Areas covered

This review describes potential biomarkers for the diagnosis of perinatal neurovascular diseases and discusses the possibilities they open for the classification and treatment of neonatal neurovascular diseases.

Expert opinion

Although high rates of ischemic and hemorrhagic stroke exist in pediatric populations, most studies have focused on biomarkers of hypoxic-ischemic encephalopathy. Inflammatory and neuronal biomarkers such as S-100B and GFAP, in combination with others yet to be discovered, could be considered as part of multiplex panels to diagnose these diseases and potentially for monitoring response to treatments. Ideally, noninvasive biofluids would be the best source for evaluating these biomarkers in proteomic assays in perinatal patients.

中文翻译：

---

从围产期神经血管病变的蛋白质组分析中吸取的教训。

介绍

与神经血管疾病相关的围产期和儿科疾病会在生活中引起重大问题，影响预期寿命较长的人群。早期诊断和评估这些疾病的严重程度对于建立适当的神经保护治疗至关重要。目前，体格检查、神经影像学和临床判断是诊断的主要工具，尽管这些检查有一定的局限性。人们对无创生物标志物的潜在价值越来越感兴趣，这些生物标志物可用于监测有脑损伤风险的儿童患者，从而实现准确和可重复的测量。

覆盖区域

本综述描述了用于诊断围产期神经血管疾病的潜在生物标志物，并讨论了它们为新生儿神经血管疾病的分类和治疗开辟的可能性。

专家意见

尽管儿童人群中缺血性和出血性中风的发生率很高，但大多数研究都集中在缺氧缺血性脑病的生物标志物上。炎症和神经元生物标志物，如 S-100B 和 GFAP，与其他尚未发现的生物标志物相结合，可被视为诊断这些疾病并可能监测治疗反应的多重组合的一部分。理想情况下，无创生物流体将是在围产期患者的蛋白质组学分析中评估这些生物标志物的最佳来源。